Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation

Abstract Background Reduced cardiac autophagy, inflammation, and apoptosis contribute to cardiovascular complications caused by metabolic syndrome (MetS). It is documented that the nuclear receptor 4A2 (NR4A2) could modulate autophagy and apoptosis in cardiac complications. The aim of this investiga...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiyan Dai, Bo Liang, Yaolin Sun
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Online Access:https://doi.org/10.1186/s12906-025-04749-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832586042988822528
author Xiyan Dai
Bo Liang
Yaolin Sun
author_facet Xiyan Dai
Bo Liang
Yaolin Sun
author_sort Xiyan Dai
collection DOAJ
description Abstract Background Reduced cardiac autophagy, inflammation, and apoptosis contribute to cardiovascular complications caused by metabolic syndrome (MetS). It is documented that the nuclear receptor 4A2 (NR4A2) could modulate autophagy and apoptosis in cardiac complications. The aim of this investigation was to assess the therapeutic potential of luteolin, with documented beneficial properties, against MetS-associated cardiac injury. Methods Forty male albino Wistar rats were divided into 5 groups randomly as controls, MetS, and MetS animals treated with luteolin (25, 50, 100 mg/kg ip). The animal’s weight, blood pressure, lipid profile, tolerance to glucose and insulin, and cardiac histopathology were evaluated. Moreover, troponin T, creatine kinase-myocardial band (CK-MB), inflammatory profile (IL-6, IL-1β, TNF-α), transforming growth factor-β1 (TGF-β1), oxidative stress, and matrix metalloproteinase-9 (MMP-9) were analyzed to determine the cardiac state. Cardiac NR4A2 and p53, as well as apoptotic (B-cell leukemia/lymphoma 2 [BCL-2], Caspase [CASP]-3, and CASP-9) and autophagic mediators (Sequestosome-1/p62, Microtubule-associated protein 1 A/1B-light chain 3 [LC3], and Beclin-1) were measured by RT-qPCR and ELISA. Results Luteolin remarkably restored MetS-induced biochemical derangements and related cardiac injury via the suppression of apoptosis, inflammation, and stress but promotion of autophagy (p-value < 0.001). Conclusion Current findings revealed the promising therapeutical properties of luteolin against MetS-associated cardiovascular risks.
format Article
id doaj-art-2e14f16f4f89411982734b52653eaac4
institution Kabale University
issn 2662-7671
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Complementary Medicine and Therapies
spelling doaj-art-2e14f16f4f89411982734b52653eaac42025-01-26T12:15:13ZengBMCBMC Complementary Medicine and Therapies2662-76712025-01-0125111210.1186/s12906-025-04749-6Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulationXiyan Dai0Bo Liang1Yaolin Sun2Department of Comprehensive, Maoming People’s HospitalDepartment of MRI, Maoming People’s HospitalDepartment of Cardiovascular Medicine, First Hospital of Northwest UniversityAbstract Background Reduced cardiac autophagy, inflammation, and apoptosis contribute to cardiovascular complications caused by metabolic syndrome (MetS). It is documented that the nuclear receptor 4A2 (NR4A2) could modulate autophagy and apoptosis in cardiac complications. The aim of this investigation was to assess the therapeutic potential of luteolin, with documented beneficial properties, against MetS-associated cardiac injury. Methods Forty male albino Wistar rats were divided into 5 groups randomly as controls, MetS, and MetS animals treated with luteolin (25, 50, 100 mg/kg ip). The animal’s weight, blood pressure, lipid profile, tolerance to glucose and insulin, and cardiac histopathology were evaluated. Moreover, troponin T, creatine kinase-myocardial band (CK-MB), inflammatory profile (IL-6, IL-1β, TNF-α), transforming growth factor-β1 (TGF-β1), oxidative stress, and matrix metalloproteinase-9 (MMP-9) were analyzed to determine the cardiac state. Cardiac NR4A2 and p53, as well as apoptotic (B-cell leukemia/lymphoma 2 [BCL-2], Caspase [CASP]-3, and CASP-9) and autophagic mediators (Sequestosome-1/p62, Microtubule-associated protein 1 A/1B-light chain 3 [LC3], and Beclin-1) were measured by RT-qPCR and ELISA. Results Luteolin remarkably restored MetS-induced biochemical derangements and related cardiac injury via the suppression of apoptosis, inflammation, and stress but promotion of autophagy (p-value < 0.001). Conclusion Current findings revealed the promising therapeutical properties of luteolin against MetS-associated cardiovascular risks.https://doi.org/10.1186/s12906-025-04749-6Metabolic syndromeCardiacAutophagyApoptosisInflammation
spellingShingle Xiyan Dai
Bo Liang
Yaolin Sun
Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation
BMC Complementary Medicine and Therapies
Metabolic syndrome
Cardiac
Autophagy
Apoptosis
Inflammation
title Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation
title_full Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation
title_fullStr Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation
title_full_unstemmed Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation
title_short Luteolin ameliorates rat model of metabolic syndrome-induced cardiac injury by apoptosis suppression and autophagy promotion via NR4A2/p53 regulation
title_sort luteolin ameliorates rat model of metabolic syndrome induced cardiac injury by apoptosis suppression and autophagy promotion via nr4a2 p53 regulation
topic Metabolic syndrome
Cardiac
Autophagy
Apoptosis
Inflammation
url https://doi.org/10.1186/s12906-025-04749-6
work_keys_str_mv AT xiyandai luteolinamelioratesratmodelofmetabolicsyndromeinducedcardiacinjurybyapoptosissuppressionandautophagypromotionvianr4a2p53regulation
AT boliang luteolinamelioratesratmodelofmetabolicsyndromeinducedcardiacinjurybyapoptosissuppressionandautophagypromotionvianr4a2p53regulation
AT yaolinsun luteolinamelioratesratmodelofmetabolicsyndromeinducedcardiacinjurybyapoptosissuppressionandautophagypromotionvianr4a2p53regulation